Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life by Torleif Tollefsrud Gjølberg, Rahel Frick, Simone Mester, Stian Foss, Algirdas Grevys, Lene Støkken Høydahl, Øystein Kalsnes Jørstad, Tilman Schlothauer, Inger Sandlie, Morten C. Moe, Jan Terje Andersen

Get full text

NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies by Corinna Lau, Martin Berner McAdam, Grethe Bergseth, Algirdas Grevys, Jack Ansgar Bruun, Judith Krey Ludviksen, Hilde Fure, Terje Espevik, Anders Moen, Jan Terje Andersen, Tom Eirik Mollnes

Get full text

A human endothelial cell-based recycling assay for screening of FcRn targeted molecules by Algirdas Grevys, Jeannette Nilsen, Kine M. K. Sand, Muluneh B. Daba, Inger Øynebråten, Malin Bern, Martin B. McAdam, Stian Foss, Tilman Schlothauer, Terje E. Michaelsen, Gregory J. Christianson, Derry C. Roopenian, Richard S. Blumberg, Inger Sandlie, Jan Terje Andersen

Get full text